We are living through the fastest period of digital growth in human history. New technologies are transforming how we live, work, connect and innovate.
Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus
AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Im
Rare diseases impact an estimated 300 million people globally, while around one in five cancers are considered a rare disease.
The Peterson Health Technology Institute (PHTI) has added hypertension and mental health to the list of digital health technologies (DHTs) that it will review for their cl
Views & Analysis
White Papers & Webinar
Podcasts & Video
The industry has been calling for a disease-agnostic event fully dedicated to the exciting new modality of peptide-based drugs.
A brand-new event has just launched in the renowned World ADC Series – the inaugural ADC Payload Summit is taking place
According to the FDA, 2024 will be the ’breakout year’ for gene therapies.
In the dynamic cell therapy landscape, where financial challenges continue to prevail, the emphasis on innovative process development becomes pivotal.